Non-exudative Age-related Macular Degeneration
| Status: | Completed |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 60 - 85 |
| Updated: | 4/17/2018 |
| Start Date: | October 2012 |
| End Date: | January 18, 2018 |
A Prospective Study Examining Patients With Non-exudative Age-related Macular Degeneration (NEAMD) of Different Severity
Age-related macular degeneration (AMD) is the most prevalent cause of vision loss in
developed countries and is often discussed in terms of the "dry" and the "wet" forms. The
"wet" form of AMD is the more advanced form of the disease and is responsible for 80% of the
legal blindness in AMD. Treatment options include a promising class of biologics called
anti-vascular endothelial growth factors, as well as photodynamic therapy and laser surgery.
These therapies can slow further vision loss, but cannot achieve recovery of lost vision. The
"wet" form of AMD is always preceded by the "dry" form. Therefore, it is reasonable to expect
that the early detection and treatment of the "dry" form may help reduce vision loss or
progression to the more damaging "wet" form. Unfortunately, symptoms appear only in advanced
stages of the "dry" form. As light sensitive cells in the macula breakdown in a process
called geographic atrophy, the patient may notice blurred central vision.
OCT is an imaging technology that can perform non-contact cross-sectional imaging of retinal
and choroidal tissue structure in real time. It is analogous to ultrasound B-mode imaging,
except that OCT measures the intensity of reflected light rather than acoustical waves.
This study aims is to use OCT technology to compare how the retinal anatomy and blood flow
differ within three severity groupings of non-exudative age-related macular degeneration
(NEAMD).
developed countries and is often discussed in terms of the "dry" and the "wet" forms. The
"wet" form of AMD is the more advanced form of the disease and is responsible for 80% of the
legal blindness in AMD. Treatment options include a promising class of biologics called
anti-vascular endothelial growth factors, as well as photodynamic therapy and laser surgery.
These therapies can slow further vision loss, but cannot achieve recovery of lost vision. The
"wet" form of AMD is always preceded by the "dry" form. Therefore, it is reasonable to expect
that the early detection and treatment of the "dry" form may help reduce vision loss or
progression to the more damaging "wet" form. Unfortunately, symptoms appear only in advanced
stages of the "dry" form. As light sensitive cells in the macula breakdown in a process
called geographic atrophy, the patient may notice blurred central vision.
OCT is an imaging technology that can perform non-contact cross-sectional imaging of retinal
and choroidal tissue structure in real time. It is analogous to ultrasound B-mode imaging,
except that OCT measures the intensity of reflected light rather than acoustical waves.
This study aims is to use OCT technology to compare how the retinal anatomy and blood flow
differ within three severity groupings of non-exudative age-related macular degeneration
(NEAMD).
Inclusion Criteria:
- Presence of mild, moderate or severe NEAMD.
- Media clarity, pupillary dilation, and subject cooperation sufficient for adequate
fundus photographs.
- Vision better than 20/200
Exclusion Criteria:
- Inability to give informed consent.
- Inability to maintain stable fixation for OCT imaging.
- A condition that, in the opinion of the investigator, would preclude participation in
the study (e.g. unstable medical status including blood pressure, cardiovascular
disease, and glycemic control).
- A concurrent ocular pathology that may contribute to vision loss (e.g., CNV, glaucoma,
visually significant cataract, optic neuropathy, diabetic retinopathy, history of
retinal surgery) or interfere with acquisition of high-quality images
- Blood pressure > 180/110 (systolic above 180 OR diastolic above 110). If blood
pressure is brought below 180/110 by anti-hypertensive treatment, subject can become
eligible.
- An ocular condition is present that, in the opinion of the investigator, might affect
or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis
or other ocular inflammatory disease, neovascular glaucoma, etc.).
- Substantial cataract that, in the opinion of the investigator, is likely to be
decreasing visual acuity by 3 lines or more (i.e., cataract would be reducing acuity
to 20/40 or worse if eye was otherwise normal).
- Unable to ambulate and take tram from clinic to where OCT is located
We found this trial at
1
site
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
